Faculty profile

David Cescon

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

David Cescon

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Principal investigator on 3 research grants (3 CIHR), most recently in 2020.
Supervised 1 trainee who won CIHR awards, most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Breast Cancer Drug Development Combination Therapy Immunotherapy Targeted Therapy Preclinical Models Tcr T Cells Cell Cycle

Latest papers

The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.
Clinical and translational radiation oncology · 2026
FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells.
Scientific reports · 2025
Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.
European journal of nuclear medicine and molecular imaging · 2024

All 14 publications

Latest funding

Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)
CIHR · 2026 · Co-investigator
$872,100
Finding vulnerabilities in advanced breast cancer from the chromatin state of repeat DNA
CIHR · 2025 · Co-investigator
$1,147,500
198Au-Nanodepot Combined with Adjuvant Auger Electron Radioimmunotherapy, Immunotherapy and Chemotherapy for Triple-Negative Breast Cancer in Metastatic Humanized Mouse Models
CIHR · 2024 · Co-investigator
$852,975

All 15 grants and awards

14 publications.

The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.

Ruicci KM, Helou J, Barry A, Ye XY, Koch CA, Croke J, Han K, Rodin D, Hahn E, Kwan JYY, Yan M, Liu FF, Lindsay P, Javor J, Bedard P, Cescon D, Kumar V, Amir E, Nadler MB, Lee R, Glicksman RM

Clinical and translational radiation oncology2026

DOI: 10.1016/j.ctro.2026.101164 PMID: 42011409

FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells.

Feng Y, Barbulescu P, Chana CK, Shirdarreh M, Yang H, Wu L, Mamand S, Kashem M, Zia A, Han M, Tsao J, Pugh T, Cescon D, Schatz DG, Sicheri F, Martin A, Pezo RC

Scientific reports2025

DOI: 10.1038/s41598-025-07723-x PMID: 40604025

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.

Kohan AA, Lupien M, Cescon D, Deblois G, Ventura M, Metser U, Veit-Haibach P

European journal of nuclear medicine and molecular imaging2024

DOI: 10.1007/s00259-023-06546-0 PMID: 38095672

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895".

Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, Cescon D, Chia S

Current oncology (Toronto, Ont.)2023

DOI: 10.3390/curroncol30050381 PMID: 37232839

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

Rayson D, Gandhi S, Joy AA, Brezden-Masley C, Gelmon KA, Sehdev S, Cescon D, Chia S

Current oncology (Toronto, Ont.)2022

DOI: 10.3390/curroncol29120778 PMID: 36547192

If we build it they will come: targeting the immune response to breast cancer.

Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA

NPJ breast cancer2019

DOI: 10.1038/s41523-019-0133-7 PMID: 31700993

MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.

Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM

Molecular pharmaceutics2019

DOI: 10.1021/acs.molpharmaceut.9b00422 PMID: 31242384

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL

Journal for immunotherapy of cancer2019

DOI: 10.1186/s40425-019-0541-0 PMID: 30867072

Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Safikhani Z, Smirnov P, Thu KL, Silvester J, El-Hachem N, Quevedo R, Lupien M, Mak TW, Cescon D, Haibe-Kains B

Nature communications2018

DOI: 10.1038/s41467-017-02136-5 PMID: 29317617

Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Safikhani Z, Smirnov P, Thu KL, Silvester J, El-Hachem N, Quevedo R, Lupien M, Mak TW, Cescon D, Haibe-Kains B

Nature communications2017

DOI: 10.1038/s41467-017-01153-8 PMID: 29066719

Something wrong or missing on this profile? Suggest a correction

David Cescon

Research

Latest papers

Latest funding

The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.

FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells.

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895".

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.

If we build it they will come: targeting the immune response to breast cancer.

MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Gene isoforms as expression-based biomarkers predictive of drug response in vitro.

Frequent collaborators

Benjamin Haibe-Kains

Mathieu Lupien

Kathy Han

Kelsie Thu

Danielle Rodin

Jennifer Croke

Stephanie Lheureux

Eitan Amir

Lily Zhou

Michael Yan

Philippe Bedard

Patrick Veit-Haibach

Fei-Fei Liu

Samuel Aparicio

Laurie Ailles

Jason Wong

Trevor Pugh

Tracy McGaha

Anna Spreafico

Frank Sicheri

Chiara Gorrini

Alberto Martin